Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial

计划入组 396 人 · 首次发布于 2016 年 8 月 16 日

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

计划入组 37 人 · 首次发布于 2016 年 12 月 7 日

Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

计划入组 46 人 · 首次发布于 2018 年 8 月 9 日

Quizartinib(Vanflyta)

C₂₉H₃₂N₆O₄S

Exon 44 Duplication(CRD)

Exon 28 Duplication(CRD)

Tandem Diabetes Care

Internal Medicine Associates

United States

TANDEM DIABETES CARE, INC.

United States

Invivoscribe's LabPMM Secures New York State Approval for Ultra-Sensitive FLT3 ITD MRD Assay in AML

LeukoStrat® CDx FLT3 Mutation Assay Receives EU Approval for AML Treatment Selection

MRD Status and Remission Number Impact HSCT Outcomes in AML